BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of “Moderate Buy” by Analysts

BridgeBio Pharma, Inc. (NASDAQ:BBIO) has been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $47.62.

Several analysts recently issued reports on the company. Evercore ISI assumed coverage on BridgeBio Pharma in a report on Tuesday, May 14th. They issued an “outperform” rating and a $50.00 price target for the company. Citigroup increased their price target on BridgeBio Pharma from $42.00 to $46.00 and gave the company a “buy” rating in a report on Friday, February 23rd. HC Wainwright restated a “buy” rating and set a $43.00 target price on shares of BridgeBio Pharma in a research note on Wednesday, June 5th. UBS Group lowered their target price on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Finally, JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Randal W. Scott sold 1,000 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $28.84, for a total value of $28,840.00. Following the transaction, the director now owns 5,500 shares in the company, valued at $158,620. The transaction was disclosed in a document filed with the SEC, which is available at this link. 24.66% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. YHB Investment Advisors Inc. acquired a new position in shares of BridgeBio Pharma in the 1st quarter valued at $34,000. Quarry LP bought a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $50,000. EntryPoint Capital LLC bought a new stake in BridgeBio Pharma during the first quarter worth about $117,000. Assetmark Inc. grew its stake in shares of BridgeBio Pharma by 46.8% in the fourth quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after buying an additional 935 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in BridgeBio Pharma in the 3rd quarter valued at about $132,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Stock Up 1.4 %

Shares of BridgeBio Pharma stock opened at $27.61 on Thursday. BridgeBio Pharma has a fifty-two week low of $14.78 and a fifty-two week high of $44.32. The firm has a market cap of $5.17 billion, a PE ratio of -8.57 and a beta of 1.08. The business’s fifty day moving average is $27.50 and its two-hundred day moving average is $31.95.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.35. The firm had revenue of $211.12 million during the quarter, compared to analysts’ expectations of $140.06 million. Equities research analysts anticipate that BridgeBio Pharma will post -3.2 EPS for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.